Product Information

Contents: Carrier-Free Recombinant Human IL-29
Catalog Number: 34-8299
Sizes: 100 ug, 500 ug
Formulation: Sterile liquid; phosphate buffered saline, pH 7.2, 150 mM NaCl, 1.0% BSA. 0.22 µM filtered.
Storage Conditions: For greatest stability, keep concentration of primary stock at or above 10 µg/ml. For long term storage, aliquot into polypropylene vials (volumes of 20 µl or greater) and store at or below -80°C. Avoid repeated freeze/thaw cycles.
Handling Conditions: For best recovery, always quick-spin vial prior to opening. For dilution of current stock (100 ug/ml), always include carrier protein (1% BSA or 10% FBS) in the buffered saline diluent.
Source: E. coli expressed amino acids gly 20-thr 200 of mature human IL-29 (accession # NM_172140).
Molecular Mass: The protein is not methionylated at the N-terminal and has a predicted molecular mass of 20,018. The DTT reduced protein migrates as a 20 kDa band on SDS-PAGE. The non-reduced protein migrates as a 19 kDa protein on non-reduced SDS-PAGE.
Purity: Greater than 98% as determined by SDS-PAGE
Endotoxin Level: Less than 0.01 ng/ug cytokine as determined by the LAL assay.
Bioactivity: Measured in an assay of inhibition of the cytopathic effect of EMC virus on HepG2 cells. The ED₅₀ for this effect is typically below 0.50 ng/ml, corresponding to a specific activity of >2.0 x 10⁶ U/mg.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
14-8299	Recombinant Human IL-29 (Interleukin-29, IL29)	N/A	N/A	BA ELISA
34-8299	Carrier-Free Recombinant Human IL-29 (Interleukin-29, IL29)	N/A	N/A	BA ELISA
39-8299	Single-Use ELISA RSG Standard Recombinant Human IL-29 (Interleukin-29, IL29)	N/A	N/A	ELISA

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

IFN-λs are a novel family of interferons which mediate the induction of anti-viral protection in a wide variety of cells. The three members of the IFN-λ family are λ1, λ2, and λ3, also known as IL-29, IL-28A, and IL-28B, respectively. IFN-λs share with type I IFNs an intracellular signaling pathway that drives the expression of a common set of IFN-stimulated genes. IFN-lambdas induce multiple biological activities, including the upregulation of class I MHC gene product expression to levels comparable to those induced by IFN-αs. IL-28 and IL-29 are tested for anti-viral activity by challenging the human hepatocellular carcinoma cell line HepG2 with infection by EMC (following pretreatment of the cells with cytokine).

Consistent with a role in anti-viral protection, the mRNA expression of IFN-lambdas is detectable in cells infected with various viruses. Moreover, monocyte-derived dendritic cells (important producers of IFN-α) express IFN-λ1 mRNA in response to treatment with dsRNA. TLR3 and TLR4 ligands induce IFN-α, IFN-β, IL-28, and IL-29 gene expression in macrophages; this is dependent upon IFN-α.

IFN-lambdas mediate their anti-viral protection through a class II cytokine receptor complex distinct from that of type I IFNs. This is comprised of two essential receptor proteins, CRF2-12/IFN-λR1, which is unique to IFN-lambdas, and CFR2-4/IL-10R2, which is shared with IL-10, IL-22, and IL-26 receptors. Whereas, the two chains of the type I IFN receptor (IFN-AR1 and IFN-AR2) and IL-10R2 are ubiquitously expressed, IFN-λR1 expression is limited and cell-type dependent. IFN-λR1 is not expressed by monocytes, but is up-regulated during GM-CSF/IL-4 induced differentiation of DCs from human monocytes, yielding iDCs which are fully responsive to IFN-λ.

The IFN-λs, IL-28 and IL-29, have recently been reported to prime dendritic cells to induce proliferation of Foxp3-bearing regulatory T cells. IFN-λ-matured DCs express high levels of class I and II MHC gene products, but low levels of costimulatory molecules, and are able to specifically induce IL-2-dependent proliferation of CD4+CD25+FOXP3+ T cell population with contact dependent suppressive activity on T cells.

Applications Reported

For research use only, not for diagnostic or therapeutic use. Recombinant human IL-29 is biologically active and is reported for use in biological assay.

Applications Tested

The recombinant human IL-29 has been tested for inhibition of the cytopathic effect of EMC virus on HepG2 cells. The ED₅₀ for this effect is typically below 0.50 ng/ml, corresponding to a specific activity of >2.0 x 10⁶ U/mg.

References

Kotenko, S., et al. 2003. IFN-lambdas mediate anti-viral protection through a distinct class II cytokine receptor complex. Nature Immunol. 4: 69-77.
Mennechet, F., et al. 2006. IFN-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Immunobiology. 107: 4417-4423.
Sheppard, P., et al. 2003. IL-28, IL-29, and their class II cytokine receptor IL-28R. Nature Immunol. 4: 63-68.

Related Products

Cat. 88-7906 Human IL-10 (Interleukin-10, IL10) ELISA Ready-SET-Go! Kit (with Pre-Coated Plates)
Cat. 34-8109 Carrier-Free Recombinant Human IL-10 (Interleukin-10, IL10)